Multinationals Step Up Clinical Trials In South Korea
This article was originally published in PharmAsia News
Executive Summary
SEOUL - More and more multinational companies are coming to South Korea to conduct clinical trials, taking advantage of the country's well-trained workforce, well-established infrastructure, lower cost compared with other advanced countries and competitive R&D capability
You may also be interested in...
Korea FDA To Consider Substantial Reduction To IND Timeframe
As Korea competes with neighboring countries to be a regional clinical trial hub, KFDA weighs the advantages of slashing IND timelines from 30 days down to 14 days.
Korea FDA To Consider Substantial Reduction To IND Timeframe
As Korea competes with neighboring countries to be a regional clinical trial hub, KFDA weighs the advantages of slashing IND timelines from 30 days down to 14 days.
Japan's Otsuka Holds Talks With Korean Government On R&D Project
SEOUL - The Korean unit of Japan's Otsuka Pharmaceuticals is holding negotiations with South Korea's Ministry for Heath, Welfare and Family Affairs on investing in drug research and development, and the two sides could soon sign a memorandum of understanding, according to a Korea Otsuka executive